Response to the points to consider for immunotherapy of malignancy by in vivo gene transfer into tumors.
D000818:Animals; D002985:Clinical Protocols; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000627:therapeutic use*; D015316:Genetic Therapy; D015793:HLA-B7 Antigen / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D007518:Isoantibodies / Q000096:biosynthesis*; D007519:Isoantigens / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C / Q000235:genetics; D009369:Neoplasms / Q000628:therapy*; D012449:Safety
D004274:DNA, Recombinant; D015793:HLA-B7 Antigen; D007518:Isoantibodies; D007519:Isoantigens